
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharmaceuticals Inc. has demonstrated strong sales momentum, particularly with Baqsimi, which saw a significant approximately 20% quarter-over-quarter increase in prescriptions during the third quarter of 2025, aided by seasonal factors and collaborative sales efforts. The company anticipates a return to double-digit growth starting in 2026, with expectations of high-single-digit unit growth for Baqsimi in 2025, which positions Amphastar favorably against its peers in terms of revenue and price-to-earnings ratios. Additionally, products like Primatene Mist have performed strongly, indicating robust demand that may further support the company's financial growth in the upcoming seasons.
Bears say
Amphastar Pharmaceuticals Inc is experiencing significant challenges in its revenue projections due to increased competition and supply issues affecting its products, particularly iron sucrose and glucagon, with expected sales declining to below $70 million in the upcoming years. The competition landscape has evolved from a sole player to a four-player market for glucagon, leading to moderated growth expectations, with top-line growth forecasts downgraded from double digits to high-single digits or low double digits for 2026. Consequently, these developments indicate ongoing pressure on Amphastar's sales and may adversely impact the company's financial stability moving forward.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares